Kiley Juergens Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kiley Juergens Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-284	Closed	-$54K	–	642
2018 Q3	$54K	Buy	284 +9	+3%	+$1.6K	0.04%	230
2018 Q2	$0	Buy	+275	New	+$42.6K	﹤0.01%	697
2018 Q1	–	Sell	-275	Closed	-$41K	–	598
2017 Q4	$41K	Buy	+275	New	+$40.7K	0.04%	222

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kiley Juergens Wealth Management's VRTX Position: Q4 2018 in Review

Kiley Juergens Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 284 shares — an estimated $54K sold.

Kiley Juergens Wealth Management first reported a position in VRTX in Q4 2017 and held it in 3 quarters. The position peaked at $54K in Q3 2018. 705 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

Kiley Juergens Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Kiley Juergens Wealth Management sold 284 Vertex Pharmaceuticals shares in Q4 2018, an estimated $54K.
Kiley Juergens Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 3 quarters.
Kiley Juergens Wealth Management's Vertex Pharmaceuticals position peaked at $54K in Q3 2018.
705 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on Kiley Juergens Wealth Management's 13F filing for Q4 2018, filed 15 Jan 2019.